Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJP-0008 Phase I QT/QTc Evaluation Study
jRCT2031210280Phase 1Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SJP-0008 in central retinal artery occlusion (CRAO) (3 arms), sponsored by Senju Pharmaceutical Co., Ltd. Primary endpoint: Prolongation of QT/QTc interval. Started Sep 2021; status: completed.
02
Drugs
SJP-0008
03
Conditions
central retinal artery occlusion (CRAO)
Beyond the preview
Go deeper on jRCT2031210280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210280.